These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37143128)

  • 1. A Study of Individualized Diagnosis and Treatment for Depression with Atypical Features (iDoT-AFD): study protocol for a randomized clinical trial and prognosis study.
    Zhou R; Zhang H; He S; Li Y; Xu G; Huang J; Wang H; Wang Q; Li B; Wang X; Chen N; Li F; Li X; Liu M; Peng D
    Trials; 2023 May; 24(1):308. PubMed ID: 37143128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of patients with major depressive disorder switching SSRI/SNRI therapy compared with those augmenting with an atypical antipsychotic in a real-world setting.
    Kern DM; Cepeda MS; Castilla-Puentes RC; Savitz A; Etropolski M
    Curr Med Res Opin; 2021 Aug; 37(8):1377-1384. PubMed ID: 33818238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient decision aid for antidepressant use in pregnancy: study protocol for a randomized controlled trial.
    Vigod S; Hussain-Shamsy N; Grigoriadis S; Howard LM; Metcalfe K; Oberlander TF; Schram C; Stewart DE; Taylor VH; Dennis CL
    Trials; 2016 Feb; 17(1):110. PubMed ID: 26923796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between the loudness dependence of auditory evoked potential, serotonergic neurotransmission and treatment outcome in patients with depression.
    Ip CT; Ganz M; Ozenne B; Olbrich S; Beliveau V; Dam VH; Köhler-Forsberg K; Jørgensen MB; Frøkjær VG; Knudsen GM
    Eur Neuropsychopharmacol; 2023 May; 70():32-44. PubMed ID: 36863106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
    Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
    BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study.
    Castellano S; Ventimiglia A; Salomone S; Ventimiglia A; De Vivo S; Signorelli MS; Bellelli E; Santagati M; Cantarella RA; Fazio E; Aguglia E; Drago F; Di Nuovo S; Caraci F
    CNS Neurol Disord Drug Targets; 2016; 15(10):1290-1298. PubMed ID: 27712575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4.
    Nonen S; Kato M; Takekita Y; Wakeno M; Sakai S; Serretti A; Kinoshita T
    J Clin Psychopharmacol; 2016 Feb; 36(1):27-31. PubMed ID: 26674707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study.
    McIntyre RS; Prieto R; Schepman P; Yeh YC; Boucher M; Shelbaya A; Chambers R; Gao X; Pappadopulos E
    Curr Med Res Opin; 2019 Dec; 35(12):2169-2177. PubMed ID: 31370711
    [No Abstract]   [Full Text] [Related]  

  • 13. Serotonin 1A Receptor Binding of [11C]CUMI-101 in Bipolar Depression Quantified Using Positron Emission Tomography: Relationship to Psychopathology and Antidepressant Response.
    Lan MJ; Zanderigo F; Pantazatos SP; Sublette ME; Miller J; Ogden RT; Mann JJ
    Int J Neuropsychopharmacol; 2022 Aug; 25(7):534-544. PubMed ID: 34996114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment.
    Fagiolini A; Florea I; Loft H; Christensen MC
    J Affect Disord; 2021 Mar; 283():472-479. PubMed ID: 33516560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies.
    Papakostas GI; Cooper-Kazaz R; Appelhof BC; Posternak MA; Johnson DP; Klibanski A; Lerer B; Fava M
    Int Clin Psychopharmacol; 2009 Jan; 24(1):19-25. PubMed ID: 19092448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.
    Lv X; Si T; Wang G; Wang H; Liu Q; Hu C; Wang J; Su Y; Huang Y; Jiang H; Yu X
    BMC Psychiatry; 2016 Jul; 16():240. PubMed ID: 27422150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery.
    Herrera-Guzmán I; Gudayol-Ferré E; Herrera-Abarca JE; Herrera-Guzmán D; Montelongo-Pedraza P; Padrós Blázquez F; Peró-Cebollero M; Guàrdia-Olmos J
    J Affect Disord; 2010 Jun; 123(1-3):341-50. PubMed ID: 19896719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.